首页> 外文期刊>Current urology. >The Floppy Iris Syndrome -What Urologists and Ophthalmologists Need to Know
【24h】

The Floppy Iris Syndrome -What Urologists and Ophthalmologists Need to Know

机译:软盘虹膜综合征-泌尿科医师和眼科医师需要了解的知识

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Benign prostatic hyperplasia (BPH) and cataract formation are common in older people. Medical management of symptomatic BPH is often preferred to surgical treatment as surgery increases the risk of morbidities, whereas, surgery is the main form of treatment to restore sight in patient with cataract. The clinical treatment of BPH is either alpha-1 adrenergic antagonist alone or combination of alpha reductase inhibitor and alpha adrenergic receptor (AR) antagonist. There are four alpha-AR antagonists currently available to treat BPH. The uroselective alpha-blocker tam-sulosin is the most commonly used drug among all. Studies showed that the majority of the patients who develop intra-operative floppy iris syndrome (IFIS) were on tamsulosin. Women are more likely to develop cataract than men and some recent studies showed that tamsulosin is effective in treating female lower urinary tract symptoms and thereby can cause IFIS during cataract surgery. Evidence Acquisi-tion: We performed a critical review of the published articles and abstracts on association of IFIS with alpha-blockers and other medications as well as other medical conditions. Evidence Synthesis: Tamsulosin is the most common cause of formation of IFIS. However, not all patients given tamsulosin develop IFIS and cases have been reported without any tamsulosin treatment.
机译:简介:良性前列腺增生(BPH)和白内障形成在老年人中很常见。有症状的BPH的医学管理通常比手术治疗更可取,因为手术会增加患病的风险,而手术是恢复白内障患者视力的主要治疗形式。 BPH的临床治疗是单独使用α-1肾上腺素拮抗剂或将α还原酶抑制剂和α肾上腺素受体(AR)拮抗剂联合使用。目前有四种α-AR拮抗剂可用于治疗BPH。尿选择性α-阻滞剂坦索罗辛是所有药物中最常用的药物。研究表明,术中出现软性虹膜综合症(IFIS)的大多数患者使用坦洛新。女性比男性更容易患白内障,一些最新研究表明,坦索罗辛可有效治疗女性下尿路症状,从而在白内障手术中引起IFIS。证据获取:我们对IFIS与α受体阻滞剂和其他药物以及其他医疗状况之间的关联对发表的文章和摘要进行了严格的审查。证据综合:坦洛新是形成IFIS的最常见原因。但是,并非所有接受坦索罗辛治疗的患者都发展为IFIS,据报道该病例未经坦索罗辛治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号